


## GPEI nOPV2 Working Group Structure and Linkages



The nOPV2 Working Group was established to manage and coordinate GPEI’s activities to enable a rapid and effective roll out of nOPV2 as the tool of choice for responding to cVDPV2 outbreaks. The working group will focus on the following, through the development, implementation and management of workplans and budgets for the following areas of work:

- **Research:** Support new clinical trials and pilot field-projects through provision of technical guidance, ensuring field operational needs are met; coordinate operations monitoring/studies of initial field use of nOPV2 and dissemination of results and reports across stakeholders
- **Regulatory:** Support fast-track submission under WHO’s Emergency Use Listing Procedure (EUL), and eventual full licensure, along with WHO prequalification
- **Supply:** Ensure the availability of nOPV2, in sufficient quantities, and establish risk mitigation strategies
- **Implementation Readiness:** Plan for the deployment of nOPV2, including providing technical guidance for decision making and training, regulatory approvals and continued surveillance and monitoring following use; coordinate laboratory and diagnostics work to enable strain identification
- **Communications:** Ensure stakeholders and countries have timely and accurate information about nOPV2 to support its use, including assessing feasibility of conducting behavioral and anthropological research, developing crisis communications strategies and proactive information dissemination
- **Policy:** Work with SAGE and its polio working group to develop prioritization guidance for the initial use of nOPV2, including priority countries and strategies, provide guidance on candidate selection and manufacturing decisions for nOPV2 as needed
- **Genetic Characterization:** Support BioFarma’s fulfillment of its obligations under the EUL related to monitoring of the genetic stability of nOPV2 (time-limited subgroup)

Each GPEI partner has nominated one person as their core nOPV2 working group member, along with an alternate who also functions as a member of the core group. The nOPV2 WG has also established sub-groups and identified nOPV2-specific liaisons to oversee each of the critical areas of work. These include sub-groups on clinical/pilot studies, regulatory, implementation readiness, and liaisons to the VSTT for supply and the SCWG on communications.

The nOPV2 WG meets bi-weekly by teleconference (TC). In-person meetings will be arranged by the Secretariat at least once a year. Sub-groups have set up their own operating rhythm but are expected to hold a TC at least once per month

The nOPV2 WG maintains close links with the OPRTT, RRTs, VSTT, Strategic Communications Working group, PACT comms team, the Hub, FMT and other GPEI groups to ensure coordination of activities and avoid duplication.

Please [click here](#) to review the nOPV2 WG's Terms of Reference.